HER-dimerization inhibitors: Evaluating pertuzumab in women's cancers

Expert Opinion on Biological Therapy

Volumn 10, Issue 2, 2010, Pages 243-250

  Kristjansdottir, Katrin ^a   Dizon, Don ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Breast cancer; HER2; Ovarian cancer; Pertuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN; GCD 0941; GEFITINIB; GEMCITABINE; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PERTUZUMAB; PHOSPHOPROTEIN; PLACEBO; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN MCF 7; CHO CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE FREE INTERVAL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; GENE OVEREXPRESSION; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAIN; PERICARDIAL EFFUSION; PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RECURRENT CANCER; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; SMALL INTESTINE OBSTRUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DIMERIZATION; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 76149140525     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903514090     Document Type: Review

References (44)

1. What you need to know about breast cancer. Bethesda, Maryland: National Cancer Institute. Available from: http:// www.cancer.gov/cancertopics/types/ breast [Last Accessed November 2009]
2. Ovarian Cancer. Bethesda, Maryland: National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/types/ ovarian [Last accessed 10 November 2009]
3. Baselga J, Tripathy D, Medelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14(3):737-744
4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study on the efficacy and safetu of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancerthat has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-726
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-792
7. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19(10):2587-2595
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-1684
9. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-postitive breast cancer [abstract 512]. J Clin Oncol 2007;25(Suppl)
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-1672
11. Joensuu H, Kellokumpu-Lehthinn PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;284:122-130
12. Robert NJ, Eiermann W, Pienkowski T, et al. BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up [abstract 19647]. J Clin Oncol 2007;25 (Suppl)
13. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96
14. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarianor primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncolgy Group. J Clin Oncol 2003;21(2):283-290
15. Geyer CE, Forster MD, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-2743
16. Grunwald V, Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer 2002;26:109-164
17. Yarden Y, Sliwkowski MX. Untangling the Erb B signaling network. Nat Rev Mol Cell Biol 2001;2:127-137
18. Natha R, Yuan LXH, Zhang B, et al. Insulin-like growth factor-I Receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65(23):11118- 11128
19. Cho HS, Mason K, Ramayar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:757-760
20. Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB-2 pertuzumab complex. Cancer Cell 2004;5(4):317-328
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
22. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137
23. Lewis GD, Lofgren JA, McMurtrey AE, et al. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996;56:1457-1465
24. Mann M, Sheng H, Shao J, et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001;120:1713-1925
25. Natha R, Hung MC, Esteva F. The HER-2-targeting antibodies trastuzumaband pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-2346
26. Yao E, Zhou W, Lee-Hoenflich ST, et al. Suppression of HER2/ HER3-mediatedgrowth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor,trastuzumab and pertuzumab. Clin Cancer Res 2009;15(12):4147-4155
27. Friess T, Bauer S, Burger AM, et al. In vivo activity of recombinanat humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER2 overexpression [abstract 496]. Eur J Cancer 2002;38 (Suppl 7):S149
28. Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005;11(14):5300-5309
29. Pohl M, Stricker I, Schoeneck A, et al. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. J Cancer Res Clin Oncol 2009;135(10):1377-1386
30. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99(9)694-705
31. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to producea therapeutic HER dimerizationinhibitor, pertuzumab. Cancer Immunol Immunother 2006;55(6):717-727
32. Agus, DB, Gordon MS, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23(11):2534-2543
33. Cortes J, Basega J, Kellokumpu-Lehtinen P, et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastático breast cancer (MBC) with low expression of HER2 [abstract 3068]. J Clin Oncol 2005;23 (Suppl)
34. Gelmon KA, Fumeoleau P, Verma S, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy [abstract 1026]. J Clin Oncol 2008;26 (Suppl)
35. Cortes J, Baselga J, Petrella T, et al. Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2-positive breast cancer [abstract 155]. J Clin Oncol 2009;27 (Suppl)
36. Genentech, Inc. . A Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated her2-positive metastatic breast cancer CLEOPATRA. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00567190? term= pertuzumab&rank=14 [Last accessed 30 November 2009]
37. Hoffmann-La Roche. A randomized, open label study to compare the complete pathological response rate achieved with 4 combinations of herceptin, docetaxel and pertuzumab in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00545688? term=pertuzumab&rank=10 [Last accessed 30 November 2009]
38. Hoffmann-La Roche. A Study of pertuzumab in combination with herceptin and chemotherapy in patients with HER2-positive breast cancer. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00976989? term=pertuzumab&rank=6 [Last accessed 30 November 2009]
39. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24(26):4324-4332
40. Amler L, Makhija S, Januario T, et al. HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant ovarian cancer [abstract 5552]. J Clin Oncol 2008;26 (Suppl)
41. Dizon DS, Makhija S. HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology. Expert Opin Drug Discov 2008;3(11):1-7
42. Kaye SB, Poole CJ, Bidzinksi M, et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer [abstract 5520]. J Clin Oncol 2008;26 (Suppl)
43. Nagumo Y, Faratian D, Mullen P, et al. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implication for peruzumab sensitivity. Mol Cancer Res 2009;7(9):1563-1571
44. Natha R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006;8(6):215